<DOC>
	<DOCNO>NCT02769078</DOCNO>
	<brief_summary>The overall objective proposal execute real-world database analysis evaluate hospital readmission among hospitalized nonvalvular atrial fibrillation ( NVAF ) patient U.S .</brief_summary>
	<brief_title>Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran , Rivaroxaban , Apixaban , Warfarin In The U.S</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Have primary secondary diagnosis AF identify International Classification Diseases , Ninth Revision , Clinical Modification ( ICD9CM ) cod Cerner Health Facts hospital database January 1 , 2012 August 31 , 2014 Age 18 year old initial hospitalization AF diagnosis Have primary secondary diagnosis code procedure code valvular disease study period . This exclusion criterion consistent use previous BMS Health Economics Outcomes Research ( HEOR ) study use ensure study population NVAF patient Received multiple type NOACs index hospitalization . Preliminary analysis show patient receive multiple type NOACs hospitalization . This exclusion criterion allow cleanly group patient different New oral anticoagulant ( NOAC ) usage group</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Anticoagulation</keyword>
</DOC>